Publications by authors named "Satyin Kaura"

Claim this Profile
T
The Value of Survival Gains in Pancreatic Cancer from Novel Treatment Regimens.
Joanna P MacEwan, Wes Yin, Satyin Kaura, Zeba M Khan

J Manag Care Spec Pharm· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The value of survival gains in myelodysplastic syndromes.
Joanna P MacEwan, Wes Yin, Satyin Kaura, Zeba M Khan

Am J Manag Care· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orphan Drug Expenditures In The United States: A Historical And Prospective Analysis, 2007-18.
Victoria Divino, Mitch DeKoven, Michael Kleinrock, Rolin L Wade, Satyin Kaura

Health Aff (Millwood)· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.
Victoria Divino, Mitch DeKoven, Michael Kleinrock, Rolin L Wade, Tony Kim, Satyin Kaura

Orphanet J Rare Dis· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abraxane® versus Taxol® for patients with advanced breast cancer: A prospective time and motion analysis from a Chinese health care perspective.
George Dranitsaris, Bo Yu, Leiping Wang, Weili Sun, Yan Zhou, Satyin Kaura

J Oncol Pharm Pract· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective.
George Dranitsaris, Bo Yu, Jennifer King, Satyin Kaura, Adams Zhang

Clinicoecon Outcomes Res· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of patient programs on adherence and persistence in inflammatory and immunologic diseases: a meta-analysis.
Chakkarin Burudpakdee, Zeba M Khan, Smeet Gala, Merena Nanavaty, Satyin Kaura

Patient Prefer Adherence· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis.
Sonya J Snedecor, John A Carter, Satyin Kaura, Marc F Botteman

J Med Econ· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective.
Thomas E Delea, Jason Rotter, Matthew Taylor, David Chandiwana, Manjinder Bains, Satyin Kaura

J Med Econ· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid.
Henry Henk, April Teitelbaum, Satyin Kaura

Curr Med Res Opin· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Henry J Henk, Satyin Kaura

J Med Econ· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers.
Henry J Henk, Satyin Kaura

J Med Econ· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases.
Henry J Henk, Satyin Kaura, April Teitelbaum

J Med Econ· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.
Sonya J Snedecor, John A Carter, Satyin Kaura, Marc F Botteman

Clin Ther· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma.
Henry J Henk, April Teitelbaum, Jose Ricardo Perez, Satyin Kaura

Am J Hematol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours.
John A Carter, Avani D Joshi, Satyin Kaura, Marc F Botteman

Pharmacoeconomics· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United kingdom.
Avani D Joshi, John A Carter, Marc F Botteman, Satyin Kaura

Clin Ther· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer.
Thomas E Delea, Charu Taneja, Oleg Sofrygin, Satyin Kaura, Michael Gnant

Clin Breast Cancer· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk-factor clustering and cardiovascular disease risk in hypertensive patients.
Derek Weycker, Gregory A Nichols, Maureen O'Keeffe-Rosetti, John Edelsberg, Zeba M Khan, Satyin Kaura

Am J Hypertens· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis